Dr. François Emond completed his medical degree at Laval University in 1997 and his residency in adult neurology in 2002. After a clinical fellowship in multiple sclerosis at The Ottawa Hospital under the direction of Dr. Mark S. Freedman, he joined the neurology department of the CHU of Quebec-Hôpital de l’Enfant-Jésus. Since 2012, he has been director of the multiple sclerosis clinic at the CHU of Quebec and IRDPQ (CIUSSS Capitale-Nationale – François-Charron Centre). In addition to following several hundred patients with multiple sclerosis, he regularly participates in teaching students, externs and residents of the RUIS-Laval network.
Since 2003, Dr. Emond has been involved, as primary local investigator or co-investigator, in multiple clinical trials on the long-term treatment of multiple sclerosis.
Département des sciences neurologiques
Canada G1J 1Z4
Data not available
Case Report: Acute Necrotizing Encephalopathy Following COVID-19 VaccineJournal Article
Front Neurol, 13 , 2022.
Cortical morphology predicts placebo response in multiple sclerosisJournal Article
Sci Rep, 12 (1), 2022.
Sequencing of high-efficacy disease-modifying therapies in multiple sclerosis: perspectives and approachesJournal Article
Neural Regen Res, 13 (11), 2018.
Safety and efficacy of venoplasty in MS: A randomized, double-blind, sham-controlled phase II trialJournal Article
Neurology, 91 (18), 2018.
Sequencing of disease-modifying therapies for relapsing-remitting multiple sclerosis: a theoretical approach to optimizing treatmentJournal Article
Curr Med Res Opin, 34 (8), 2018.
Pulvinar sign in a case of anti-HU paraneoplastic encephalitisJournal Article
Neuroradiol J, 29 (6), 2016.
Treatment optimization in MS: Canadian MS Working Group updated recommendationsJournal Article
Can J Neurol Sci, 40 (3), 2013.
LRRK2 is not a significant cause of Parkinson's disease in French-CanadiansJournal Article
Can J Neurol Sci, 34 (3), 2007.